Teva Pharmaceutical (TEVA) Slammed Early on FY13 Warning
Tweet
Share
E-mail
Teva Pharmaceutical Industries (NYSE: TEVA) is trading down 5.3 percent following lower guidance announced moments ago.
Teva Pharmaceutical said it expects FY13 adjusted EPS of $4.85 - $5.15, versus the consensus of $5.63. The company is targeting revs of $19.5 - $20.5 billion, versus the consensus of $20.82 billion.
Teva Pharmaceutical said it expects FY13 adjusted EPS of $4.85 - $5.15, versus the consensus of $5.63. The company is targeting revs of $19.5 - $20.5 billion, versus the consensus of $20.82 billion.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nscale targets up to $3B in US IPO as soon as September - Bloomberg
- New York Fed raises Q3 2026 GDP forecast to 2.3%
- BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance
Create E-mail Alert Related Categories
Guidance, Hot Guidance, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
